🎉 M&A multiples are live!
Check it out!

Lineage Cell Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Lineage Cell Therapeutics and similar public comparables like Mesoblast, Cynata Therapeutics, and Orthocell.

Lineage Cell Therapeutics Overview

About Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.


Founded

1990

HQ

United States of America
Employees

77

Website

lineagecell.com

Financials

LTM Revenue $10.0M

LTM EBITDA -$22.0M

EV

$56.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Lineage Cell Therapeutics Financials

Lineage Cell Therapeutics has a last 12-month revenue of $10.0M and a last 12-month EBITDA of -$22.0M.

In the most recent fiscal year, Lineage Cell Therapeutics achieved revenue of $9.5M and an EBITDA of -$20.9M.

Lineage Cell Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Lineage Cell Therapeutics valuation multiples based on analyst estimates

Lineage Cell Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $8.9M $9.5M XXX XXX XXX
Gross Profit $14.0M $8.3M XXX XXX XXX
Gross Margin 156% 87% XXX XXX XXX
EBITDA -$24.0M -$20.9M XXX XXX XXX
EBITDA Margin -269% -220% XXX XXX XXX
Net Profit -$26.3M -$21.5M XXX XXX XXX
Net Margin -294% -226% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Lineage Cell Therapeutics Stock Performance

As of April 15, 2025, Lineage Cell Therapeutics's stock price is $0.

Lineage Cell Therapeutics has current market cap of $101M, and EV of $56.2M.

See Lineage Cell Therapeutics trading valuation data

Lineage Cell Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$56.2M $101M XXX XXX XXX XXX $-0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Lineage Cell Therapeutics Valuation Multiples

As of April 15, 2025, Lineage Cell Therapeutics has market cap of $101M and EV of $56.2M.

Lineage Cell Therapeutics's trades at 5.6x LTM EV/Revenue multiple, and -2.6x LTM EBITDA.

Analysts estimate Lineage Cell Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Lineage Cell Therapeutics and 10K+ public comps

Lineage Cell Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $56.2M XXX XXX XXX
EV/Revenue 5.9x XXX XXX XXX
EV/EBITDA -2.7x XXX XXX XXX
P/E -5.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Lineage Cell Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Lineage Cell Therapeutics Valuation Multiples

Lineage Cell Therapeutics's NTM/LTM revenue growth is 59%

Lineage Cell Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Over next 12 months, Lineage Cell Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Lineage Cell Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Lineage Cell Therapeutics and other 10K+ public comps

Lineage Cell Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 6% XXX XXX XXX XXX
EBITDA Margin -220% XXX XXX XXX XXX
EBITDA Growth -13% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -160% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 191% XXX XXX XXX XXX
R&D Expenses to Revenue 131% XXX XXX XXX XXX
Opex to Revenue 323% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Lineage Cell Therapeutics Public Comps

See public comps and valuation multiples for Regenerative Medicine and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
Orthocell XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Lineage Cell Therapeutics M&A and Investment Activity

Lineage Cell Therapeutics acquired  XXX companies to date.

Last acquisition by Lineage Cell Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Lineage Cell Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Lineage Cell Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Lineage Cell Therapeutics

When was Lineage Cell Therapeutics founded? Lineage Cell Therapeutics was founded in 1990.
Where is Lineage Cell Therapeutics headquartered? Lineage Cell Therapeutics is headquartered in United States of America.
How many employees does Lineage Cell Therapeutics have? As of today, Lineage Cell Therapeutics has 77 employees.
Who is the CEO of Lineage Cell Therapeutics? Lineage Cell Therapeutics's CEO is Mr. Brian M. Culley, M.S..
Is Lineage Cell Therapeutics publicy listed? Yes, Lineage Cell Therapeutics is a public company listed on ASE.
What is the stock symbol of Lineage Cell Therapeutics? Lineage Cell Therapeutics trades under LCTX ticker.
When did Lineage Cell Therapeutics go public? Lineage Cell Therapeutics went public in 1992.
Who are competitors of Lineage Cell Therapeutics? Similar companies to Lineage Cell Therapeutics include e.g. Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics, Mesoblast.
What is the current market cap of Lineage Cell Therapeutics? Lineage Cell Therapeutics's current market cap is $101M
What is the current revenue of Lineage Cell Therapeutics? Lineage Cell Therapeutics's last 12-month revenue is $10.0M.
What is the current EBITDA of Lineage Cell Therapeutics? Lineage Cell Therapeutics's last 12-month EBITDA is -$22.0M.
What is the current EV/Revenue multiple of Lineage Cell Therapeutics? Current revenue multiple of Lineage Cell Therapeutics is 5.6x.
What is the current EV/EBITDA multiple of Lineage Cell Therapeutics? Current EBITDA multiple of Lineage Cell Therapeutics is -2.6x.
What is the current revenue growth of Lineage Cell Therapeutics? Lineage Cell Therapeutics revenue growth between 2023 and 2024 was 6%.
Is Lineage Cell Therapeutics profitable? Yes, Lineage Cell Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.